The autoimmune IgG4 -associated endocrine pathology

Immunoglobulin G4-associated diseases (IgG4-AD) arethe group of chronic progressive autoimmune fibro-inflammatory pathology of various organs and tissues, characterized by their enlargement and abundant infiltration of immunoglobulin G4-positive plasma cells, as well as an increase in the level of serum immunoglobulin G4 (IgG4).In most patients, the disease is characterized by a mild course.However, there is evidence of a high incidence of malignancies in patients with IgG4-AD.Among endocrine IgG4-associated pathologies, pancreatitis with outcome in diabetes mellitus, hypophysitis and thyroiditis are described.

Laboratory examination usually reveals an increased level of IgG4. However, the concentration of IgG4 could not be used as the only diagnostic criterion.The possibility of plasmablastsdetermining as a marker of the disease is discussed.Among the imaging techniques CT, MRI and 18F-FDG-PET/CT are used.However, the most informative method of diagnosis is biopsy.

Randomized clinical trials to determine clear recommendations for the treatment of IgG4-AD were not conducted.In most cases, glucocorticoids are prescribed, and immunosuppressive therapy is sometimes used.According to the results of recent studies, the genetically engineered drug rituximab is relatively effective in inducing remission of the disease.Given the high recurrence rate and the risk of malignancy, patients with IgG4-AD require careful long-term follow-up.

Thus, the review describes the clinical manifestations of IgG4-AD, examines the possibilities of their diagnosis and presents the existing methods of treatment.However, given the fact that IgG4-AD became a separate group of autoimmune pathology less than 20 years ago, there are insufficient data on these diseases. Researches related to epidemiology, pathophysiology, diagnosis and effective treatment of IgG4-AD are actual.

IgG4-associatedpathology, pancreatitis, hypophysitis, thyroiditis

1. Himi T, Takano K, Yamamoto M, et al. A novel concept of Mikulicz's disease as IgG4-related disease. Auris Nasus Larynx. 2012;39(1):9-17. doi: 10.1016/j.anl.2011.01.023.

2. Stone JH, Zen Y, Deshpande V. IgG4-Related Disease. N Engl J Med. 2012;366(6):539-551. doi: 10.1056/NEJMra1104650.

3. Yamamoto M, Takahashi H, Shinomura Y. Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist. Nature Reviews Rheumatology. 2013;10(3):148-159. doi: 10.1038/nrrheum.2013.183.

4. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. The Lancet. 2015;385(9976):1460-1471. doi: 10.1016/s0140-6736(14)60720-0.

5. Gu W-J, Zhang Q, Zhu J, et al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation. Medicine. 2017;96(24):e6934. doi: 10.1097/md.0000000000006934.

6. Patel SM, Szostek JH. IgG4-related Systemic Disease in a Native American Man. Intern Med. 2011;50(8):931-934. doi: 10.2169/internalmedicine.50.4593.

7. Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology. 2014;22(1):1-14. doi: 10.3109/s10165-011-0508-6.

8. Takano K, Yamamoto M, Takahashi H, Himi T. Recent advances in knowledge regarding the head and neck manifestations of IgG4-related disease. Auris Nasus Larynx. 2017;44(1):7-17. doi: 10.1016/j.anl.2016.10.011.

9. Takuma K. Strategy to differentiate autoimmune pancreatitis from pancreas cancer. World Journal of Gastroenterology. 2012;18(10):1015. doi: 10.3748/wjg.v18.i10.1015.

10. Okazaki K, Uchida K, Matsushita M, Takaoka M. Autoimmune Pancreatitis. Internal Medicine. 2005;44(12):1215-1223. doi: 10.2169/internalmedicine.44.1215.

11. Leporati P, Landek-Salgado MA, Lupi I, et al. IgG4-Related Hypophysitis: A New Addition to the Hypophysitis Spectrum. The Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1971-1980. doi: 10.1210/jc.2010-2970.

12. Ohyama K, Koike H, Takahashi M, et al. Clinicopathological features of neuropathy associated with IgG4-related disease. Rinsho Shinkeigaku. 2014;54(12):1047-1049. doi: 10.5692/clinicalneurol.54.1047.

13. Caputo C, Bazargan A, McKelvie PA, et al. Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy. Pituitary. 2013;17(3):251-256. doi: 10.1007/s11102-013-0498-9.

14. Iseda I, Hida K, Tone A, et al. Prednisolone markedly reduced serum IgG4 levels along with the improvement of pituitary mass and anterior pituitary function in a patient with IgG4-related infundibulo-hypophysitis. Endocrine Journal. 2014;61(2):195-203. doi: 10.1507/endocrj.EJ13-0407.

15. Ohkubo Y, Sekido T, Takeshige K, et al. Occurrence of IgG4-related Hypophysitis Lacking IgG4-bearing Plasma Cell Infiltration during Steroid Therapy. Internal Medicine. 2014;53(7):753-757. doi: 10.2169/internalmedicine.53.0714.

16. Sosa GA, Bell S, Christiansen SB, et al. Histologically confirmed isolated IgG4-related hypophysitis: two case reports in young women. Endocrinology, Diabetes & Metabolism Case Reports. 2014. doi: 10.1530/edm-14-0062.

17. Harano Y, Honda K, Akiyama Y, et al. A Case of IgG4-Related Hypophysitis Presented with Hypopituitarism and Diabetes Insipidus. Clinical Medicine Insights: Case Reports. 2017;8:CCRep.S15352. doi: 10.4137/CCRep.S15352.

18. Cunha Neto M, Moreno L, Silva G, et al. Thickened Pituitary Stalk Associated with a Mass in the Sphenoidal Sinus: An Alarm to Suspect Hypophysitis by Immunoglobulin G4? International Archives of Otorhinolaryngology. 2015;19(03):273-276. doi: 10.1055/s-0034-1397333.

19. Ngaosuwan K, Trongwongsa T, Shuangshoti S. Clinical course of IgG4-related hypophysitis presenting with focal seizure and relapsing lymphocytic hypophysitis. BMC Endocrine Disorders. 2015;15(1). doi: 10.1186/s12902-015-0062-x.

20. Deshpande V, Huck A, Ooi E, et al. Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease. Journal of Clinical Pathology. 2012;65(8):725-728. doi: 10.1136/jclinpath-2011-200485.

21. Watanabe T, Maruyama M, Ito T, et al. Clinical features of a new disease concept, IgG4-related thyroiditis. Scandinavian Journal of Rheumatology. 2013;42(4):325-330. doi: 10.3109/03009742.2012.761281.

22. Yamamoto M, Yajima H, Takahashi H, et al. Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: Results from the SMART database. Modern Rheumatology. 2014;25(2):199-204. doi: 10.3109/14397595.2014.950036.

23. Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis & Rheumatology. 2015;67(7):1688-1699. doi: 10.1002/art.39132.

24. Carruthers MN, Khosroshahi A, Augustin T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Annals of the Rheumatic Diseases. 2015;74(1):14-18. doi: 10.1136/annrheumdis-2013-204907.

25. Takano K, Abe A, Yajima R, et al. Clinical Evaluation of Sinonasal Lesions in Patients With Immunoglobulin G4-Related Disease. Annals of Otology, Rhinology & Laryngology. 2015;124(12):965-971. doi: 10.1177/0003489415593557.

26. Della Torre E, Mattoo H, Mahajan VS, et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy. 2014;69(2):269-272. doi: 10.1111/all.12320.

27. Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Annals of the Rheumatic Diseases. 2015;74(1):190-195. doi: 10.1136/annrheumdis-2014-205233.

28. Ebbo M, Grados A, Guedj E, et al. Usefulness of 2-[18F]-fluoro-2-deoxy-d-glucose-Positron Emission Tomography/Computed Tomography for Staging and Evaluation of Treatment Response in IgG4-Related Disease: A Retrospective Multicenter Study. Arthritis Care & Research. 2014;66(1):86-96. doi: 10.1002/acr.22058.

29. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Annals of the Rheumatic Diseases. 2015;74(6):1171-1177. doi: 10.1136/annrheumdis-2014-206605.

30. Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Annals of the Rheumatic Diseases. 2015;74(8):e46-e46. doi: 10.1136/annrheumdis-2015-207625.